Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.40 |
| ▸ | RRM1 | P23921 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 4/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27384250 | 0.86 | TLR2 (0.38) | NOD1RRM1DPP7GNAI3GNAO1 | |
| SCHEMBL24340790 | 0.86 | NOD1 (0.36) | NOD1FAAHCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL25850206 | 0.83 | FAAH (0.43) | FAAHTLR2 | |
| SCHEMBL25842691 | 0.82 | DPP7 (0.34) | NOD1RRM1DPP7GNAI3GNAO1 | |
| SCHEMBL24341855 | 0.82 | FAAH (0.44) | FAAH | |
| SCHEMBL21096814 | 0.80 | FAAH (0.46) | FAAH | |
| SCHEMBL25842349 | 0.79 | — | — | |
| SCHEMBL26034080 | 0.78 | FAAH (0.47) | FAAHTLR2 | |
| SCHEMBL25843022 | 0.77 | BCHE (0.41) | NOD1CYP1A2CYP2C19 | |
| SCHEMBL25849437 | 0.76 | FAAH (0.43) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | NOD1 4881/4885RRM1 128/4885DPP7 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.